id
processing priority
4
site type
0 (generic, awaiting analysis)
review version
11
html import
20 (imported)
first seen date
2024-08-13 07:58:36
expired found date
-
created at
2024-08-13 07:58:36
updated at
2026-01-26 11:23:42
length
20
crc
17260
tld
2211
nm parts
0
nm random digits
0
nm rare letters
0
is subdomain of id
38187698 (springworkstx.com)
previous id
0
replaced with id
0
related id
-
dns primary id
0
dns alternative id
0
lifecycle status
0 (unclassified, or currently active)
deleted subdomains
0
page imported products
0
page imported random
0
page imported parking
0
count skipped due to recent timeouts on the same server IP
1
count content received but rejected due to 11-799
0
count dns errors
1
count cert errors
0
count timeouts
5
count http 429
0
count http 404
0
count http 403
0
count http 5xx
0
next operation date
2026-01-28 15:23:42
server bits
—
server ip
mp import status
20
mp rejected date
-
mp saved date
2025-12-04 05:49:37
mp size orig
36444
mp size raw text
2496
mp inner links count
6
mp inner links status
10 (links queued, awaiting import)
title
Newsroom | SpringWorks Therapeutics
description
The Investor Relations website contains information about SpringWorks Therapeutics's business for stockholders, potential investors, and financial analysts.
image
site name
SpringWorks Therapeutics
author
updated
2026-03-02 15:46:42
raw text
Newsroom | SpringWorks Therapeutics Skip to main navigation Back to SpringWorksTx.com Newsroom Contact Us Linkedin Twitter Overview News & Events Press Releases Events & Presentations Investors + Media Medical Professionals Contact Us Linkedin Twitter Newsroom The full potential of targeted oncology is waiting to be unlocked. SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany, is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors. We developed and are commercializing the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN). We are also advancing a portfolio of novel targeted therapy product candidates for patients with additional rare tumors and hematological cancers. Press Releases...
redirect type
0 (-)
block type
0 (no issues)
detected language
1 (English)
category id
-
index version
1
spam phrases
0
text nonlatin
0
text cyrillic
0
text characters
1923
text words
315
text unique words
173
text lines
78
text sentences
7
text paragraphs
2
text words per sentence
45
text matched phrases
0
text matched dictionaries
0
links self subdomains
links other subdomains
3 - cloud.typography.com, vizi.vizirecruiter.com, springworkstx.gcs-web.com
links other domains
28 - springworkstx.com
links spam adult
0
links spam random
0
links spam expired
0
links ext activities
0
links ext ecommerce
0
links ext finance
0
links ext crypto
0
links ext booking
0
links ext news
0
links ext leaks
0
links ext ugc
links ext klim
0
links ext generic
0
dol status
0
dol updated
2026-03-02 15:46:42
rss path
rss status
0 (new)
rss found date
-
rss size orig
0
rss items
0
rss spam phrases
0
rss detected language
0 (awaiting analysis)
inbefore feed id
-
inbefore status
0 (new)
sitemap path
sitemap status
0 (new)
sitemap review version
2
sitemap urls count
0
sitemap urls adult
0
sitemap filtered products
0
sitemap filtered videos
0
sitemap found date
-
sitemap process date
-
sitemap first import date
-
sitemap last import date
-